skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines crovalimabQuestion & answer

crovalimab · Medicine question

What is the estimated terminal half-life of crovalimab?

iatroX medicinesPublished 8 November 2026

The answer

Answer

The estimated terminal half-life of crovalimab is 53.1 days (CV: 39.9%).

Sources for this answer

PiaSky 340 mg solution for injection/infusionRoche Products Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 4Document updated 8 December 2025

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

crovalimab

Read the wider context, including uses, precautions and the sources behind this medicine guide.

More questions about crovalimab

Does crovalimab (PiaSky) affect the ability to drive or use machines?How does crovalimab prevent formation of the membrane attack complex?Is crovalimab contraindicated in patients with unresolved Neisseria meningitidis infection?Is crovalimab expected to interact with medicines that affect cytochrome P450 enzymes?Is crovalimab known to pass into human breast milk?Under what circumstances may crovalimab (PiaSky) be used during pregnancy?

Read the crovalimab guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX